NIKKEI 225
38,231.59 +29.22 (+0.08%) HANG SENG
18,511.15 +197.29 (+1.08%) CRUDE OIL
79.45 +0.46 (+0.58%) GOLD FUTURES
2,324.40 +2.10 (+0.09%) DOW
39,056.39 +172.13 (+0.44%) Bitcoin GBP
49,259.09 -884.43 (-1.76%)
Akebia Therapeutics, Inc. (AKBA)
After hours:
| Previous close | 1.4000 |
| Open | 1.3900 |
| Bid | 1.3800 x 1100 |
| Ask | 1.4100 x 700 |
| Day's range | 1.3300 - 1.4100 |
| 52-week range | 0.7800 - 2.4800 |
| Volume | |
| Avg. volume | 5,099,847 |
| Market cap | 293.433M |
| Beta (5Y monthly) | 0.84 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Simply Wall St.
When Can We Expect A Profit From Akebia Therapeutics, Inc. (NASDAQ:AKBA)?
With the business potentially at an important milestone, we thought we'd take a closer look at Akebia Therapeutics...
- Benzinga
FDA Approves For Akebia Therapeutics' Vafseo For Kidney Disease Associated Anemia
Wednesday, the FDA approved Akebia Therapeutics Inc (NASDAQ:AKBA) Vafseo (vadadustat) tablets for anemia due to chronic kidney disease (CKD) in adults who have been receiving dialysis for at least three months. Vafseo is a once-daily oral hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitor that activates the physiologic response to hypoxia to stimulate endogenous production of erythropoietin to manage anemia. Vafseo is now approved in 37 countries. The approval of Vafseo is based on e
- Zacks
Akebia (AKBA) Up as Vafseo Gets FDA Nod for Anemia Due to CKD
Akebia (AKBA) gains during premarket hours on Mar 28 as its key product Vafseo (vadadustat) tablets receive FDA's approval for the treatment of anemia due to chronic kidney disease.
